Correlation of PET/CT Findings and Histopathology after Neoadjuvant Therapy in Non-Small Cell Lung Cancer
- 1 January 2007
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 73 (5-6) , 316-323
- https://doi.org/10.1159/000134474
Abstract
Objectives: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis. Methods:18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/45 Gy). Results: Sixty patients [40 male/20 female, median age 56 years (34–78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUVmean (0.4–9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV >2.5 and volumes larger than the median (7.9 cm3) before resection. SUVmean was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03). Conclusions: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue.Keywords
This publication has 26 references indexed in Scilit:
- Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2004
- Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancerThe Annals of Thoracic Surgery, 2004
- Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose UseJournal of Clinical Oncology, 2003
- Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2003
- FDG–PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathologyLung Cancer, 2002
- An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancerThe Annals of Thoracic Surgery, 2002
- Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term resultsThe Annals of Thoracic Surgery, 1999
- Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.Journal of Clinical Oncology, 1998